Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Financial Results (Feb 18, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 18, 2026
Period End
February 18, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’16Jun ’16
  2. Deal closed8-K · May ’19May ’19
  3. Leadership change8-K · May ’21May ’21
  4. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K filed February 18, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter and full-year 2025 results on February 18, 2026, under Item 2.02 of this Form 8-K.

Fourth-quarter revenue was $994.2 milliona, a decrease of 0.8% from $1,002.5 million a year earlier; on an organic basis, revenue declined 2.6%. The GAAP net loss available to common shareholders was $(276.6) million, or $(5.62) per diluted share, driven by non-cash intangible asset impairments of $211.0 million and a goodwill impairment of $165.0 million in the Biologics Solutions reporting unit. Non-GAAP diluted earnings per share were $2.39, down 10.2% from $2.66.

For full-year 2025, revenue was $4.02 billionb, down 0.9%, with GAAP diluted loss per share of $(2.91) and non-GAAP diluted EPS of $10.28, down 0.4%. Segment performance was mixed. Fourth-quarter DSA net bookings improved substantially, which management cites as evidence of stabilizing biopharmaceutical demand, though DSA revenue fell 2.0% and its non-GAAP operating margin declined to 20.1% from 24.7%.

RMS revenue rose 1.0%, while Manufacturing Solutions revenue rose 0.7% on a reported basis but fell 2.1% organically. For 2026, the company guides to reported revenue growth of at least flat to +1.5%, organic revenue growth of (1.0)% to at least flat, GAAP EPS of $6.30 to $6.80c, and non-GAAP EPS of $10.70 to $11.20. The guidance excludes planned divestitures representing approximately 7% of annual revenue for 2025 and estimated 2026, and management expects a return to organic revenue growth in the second half of 2026.

Key Highlights

  1. Q4 2025 revenue of $994.2 million, down 0.8% reported and down 2.6% organically; FY2025 revenue of $4.02 billion, down 0.9%.
  2. Q4 GAAP diluted loss per share of $(5.62), including $211.0 million of intangible asset impairments and a $165.0 million goodwill impairment in Biologics Solutions; Q4 non-GAAP diluted EPS of $2.39, down 10.2%.
  3. FY2025 GAAP diluted loss per share of $(2.91) versus diluted EPS of $0.20 in 2024; FY2025 non-GAAP diluted EPS of $10.28, down 0.4%.
  4. DSA net bookings improved substantially in Q4 2025, which management cites as evidence of stabilizing biopharmaceutical demand, though DSA Q4 revenue declined 2.0%.
  5. 2026 guidance: reported revenue growth of at least flat to +1.5%, organic revenue growth of (1.0)% to at least flat, and non-GAAP EPS of $10.70 to $11.20.
  6. Guidance excludes planned divestitures representing approximately 7% of annual revenue; management expects organic revenue growth to return in the second half of 2026.
  7. Full-year 2025 GAAP operating margin fell to 0.6% from 5.6%, while non-GAAP operating margin held roughly steady at 19.8% versus 19.9%.

Frequently Asked Questions

  1. Why did Charles River report a large GAAP loss in the fourth quarter of 2025?

    The GAAP loss was driven by non-cash charges: intangible asset impairments of $211.0 million for the Biologics Solutions reporting unit (Manufacturing segment) and the Cell Solutions business (RMS segment), and a goodwill impairment of $165.0 million in Biologics Solutions. The company's GAAP net loss available to common shareholders was $(276.6) million, or $(5.62) per diluted share.

  2. How did the company's underlying profitability compare with the prior year?

    On a non-GAAP basis, fourth-quarter operating margin decreased to 18.1% from 19.9%, driven by lower revenue, higher study-related direct costs in DSA, and unfavorable revenue mix in RMS. Non-GAAP net income was $118.8 million, down 13.0%, and non-GAAP diluted EPS was $2.39, down 10.2%, also reflecting a higher tax rate.

  3. What is management's outlook for 2026?

    The company guides to reported revenue growth of at least flat to +1.5% and organic revenue growth of (1.0)% to at least flat, with GAAP EPS of $6.30 to $6.80 and non-GAAP EPS of $10.70 to $11.20. Management expects a return to organic revenue growth in the second half of 2026, supported by DSA bookings trends and the anniversary of a lost large CDMO client, partly offset by lower RMS large model revenue. The guidance excludes planned divestitures representing approximately 7% of annual revenue.

  4. What are the main drivers behind the 2026 non-GAAP EPS growth expectation?

    The company expects non-GAAP EPS to increase by approximately 4% to 9% in 2026, due to incremental cost savings from restructuring and efficiency initiatives, earnings accretion from the completed acquisition of the assets of K.F. (Cambodia) Ltd., and a lower tax rate.

  5. How is demand trending in the company's Discovery and Safety Assessment business?

    Management highlighted substantial improvement in DSA net bookings in the fourth quarter of 2025, which it said demonstrates stabilization of the biopharmaceutical demand environment. However, DSA revenue declined 2.0% in Q4 (3.3% organically), mainly from lower discovery services volume and regulated safety assessment services, and DSA's non-GAAP operating margin fell to 20.1% from 24.7%.